HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation

Cardiovascular Research

Volumn 64, Issue 3, 2004, Pages 412-420

  Azuma, Ryoko Wakizono ^a   Suzuki, Jun Ichi ^a   Ogawa, Masahito ^a   Futamatsu, Hideki ^a   Koga, Noritaka ^a   Onai, Yasuyuki ^a   Kosuge, Hisanori ^a   Isobe, Mitsuaki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Cytokine; HMG CoA reductase inhibitor; Immunology; Inflammation; Myocarditis; Nuclear factor B; T cell response

Indexed keywords

CHOLESTEROL; CYTOKINE; DRUG VEHICLE; FLUINDOSTATIN; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; LIPID; MESSENGER RNA; MYOSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL NUCLEUS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG MEGADOSE; EXPERIMENT; GENE EXPRESSION; HEART MUSCLE; HYPOTHESIS; IMMUNIZATION; INHIBITION KINETICS; LIPID BLOOD LEVEL; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MYOCARDITIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL;

ANIMALS; AUTOIMMUNE DISEASES; BLOTTING, WESTERN; CELL NUCLEUS; CELL PROLIFERATION; FATTY ACIDS, MONOUNSATURATED; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; INTERFERON TYPE II; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MODELS, ANIMAL; MYOCARDITIS; MYOCARDIUM; MYOSINS; NF-KAPPA B; RATS; RATS, INBRED LEW; T-LYMPHOCYTES;

EID: 8644268855     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2004.09.014     Document Type: Article

References (38)

1. B. Pisani, D.O. Taylor, and J.W. Mason Inflammatory myocardial diseases and cardiomyopathies Am. J. Med. 102 1997 459 469
2. A.M. Feldman, and D. McNamara Myocarditis N. Engl. J. Med. 343 2000 1388 1398
3. C. Kawai From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future Circulation 99 1999 1091 1100
4. J.E. Parrillo, H.T. Aretz, I. Palacios, J.T. Fallon, and P.C. Block The results of transvenous endomyocardial biopsy can frequently be used to diagnose myocardial diseases in patients with idiopathic heart failure. Endomyocardial biopsies in 100 consecutive patients revealed a substantial incidence of myocarditis Circulation 69 1984 93 101
5. Y. Drory, Y. Turetz, Y. Hiss, B. Lev, E.Z. Fisman, and A. Pines Sudden unexpected death in persons less than 40 years of age Am. J. Cardiol. 68 1991 1388 1392
6. C.A. Brown, and J.B. O'Connell Myocarditis and idiopathic dilated cardiomyopathy Am. J. Med. 99 1995 309 314
7. B. Lauer, K. Padberg, H.P. Schultheiss, and B.E. Strauer Autoantibodies against human ventricular myosin in sera of patients with acute and chronic myocarditis J. Am. Coll. Cardiol. 23 1994 146 153
8. M. Kodama, Y. Matsumoto, M. Fujiwara, F. Masani, T. Izumi, and A. Shibata A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction Clin. Immunol. Immunopathol. 57 1990 250 262
9. K. Fuse, M. Kodama, M. Ito, Y. Okura, K. Kato, and H. Hanawa Polarity of helper T cell subsets represents disease nature and clinical course of experimental autoimmune myocarditis in rats Clin. Exp. Immunol. 134 2003 403 408
10. Y. Okura, T. Yamamoto, S. Goto, T. Inomata, S. Hirono, and H. Hanawa Characterization of cytokine and iNOS mRNA expression in situ during the course of experimental autoimmune myocarditis in rats J. Mol. Cell Cardiol. 29 1997 491 502
11. O. Yokoseki, J. Suzuki, H. Kitabayashi, N. Watanabe, Y. Wada, and M. Aoki cis Element decoy against nuclear factor-kappaB attenuates development of experimental autoimmune myocarditis in rats Circ. Res. 89 2001 899 906
12. M.E. Ginn-Pease, and R.L. Whisler Redox signals and NF-kappaB activation in T cells Free Radic. Biol. Med. 25 1998 346 361
13. P.J. Barnes, and M. Karin Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases N. Engl. J. Med. 336 1997 1066 1071
14. R. Morishita, T. Sugimoto, M. Aoki, I. Kida, N. Tomita, and A. Moriguchi In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction Nat. Med. 3 1997 894 899
15. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
16. P.W. Serruys, P. de Feyter, C. Macaya, N. Kokott, J. Puel, and M. Vrolix Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial JAMA 287 2002 3215 3222
17. M. Takemoto, and J.K. Liao Pleiotropic effects of 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitors Arterioscler. Thromb. Vasc. Biol. 21 2001 1712 1719
18. R. Hakamada-Taguchi, Y. Uehara, K. Kuribayashi, A. Numabe, K. Saito, and H. Negoro Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development Circ. Res. 93 2003 948 956
19. B.P. Leung, N. Sattar, A. Crilly, M. Prach, D.W. McCarey, and H. Payne A novel anti-inflammatory role for simvastatin in inflammatory arthritis J. Immunol. 170 2003 1524 1530
20. A. Hilgendorff, H. Muth, B. Parviz, A. Staubitz, W. Haberbosch, and H. Tillmanns Statins differ in their ability to block NF-kappaB activation in human blood monocytes Int. J. Clin. Pharmacol. Ther. 41 2003 397 401
21. R. Dechend, A. Fiebler, C. Lindschau, H. Bischoff, D. Muller, and J.K. Park Modulating angiotensin II-induced inflammation by HMG Co-A reductase inhibition Am. J. Hypertens. 14 2001 55S 61S
22. H. Futamatsu, J. Suzuki, H. Kosuge, O. Yokoseki, M. Kamada, and H. Ito Attenuation of experimental autoimmune myocarditis by blocking activated T cells through inducible costimulatory molecule pathway Cardiovasc. Res. 59 2003 95 104
23. D.J. Sahn, A. DeMaria, J. Kisslo, and A. Weyman Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements Circulation 58 1978 1072 1083
24. S.E. Litwin, S.E. Katz, J.P. Morgan, and P.S. Douglas Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat Circulation 89 1994 345 354
25. H. Kosuge, J. Suzuki, R. Gotoh, N. Koga, H. Ito, and M. Isobe Induction of immunologic tolerance to cardiac allograft by simultaneous blockade of inducible co-stimulator and cytotoxic T-lymphocyte antigen 4 pathway Transplantation 75 2003 1374 1379
26. N.R. Ratcliffe, J. Hutchins, B. Barry, and W.F. Hickey Chronic myocarditis induced by T cells reactive to a single cardiac myosin peptide: persistent inflammation, cardiac dilatation, myocardial scarring and continuous myocyte apoptosis J. Autoimmun. 15 2000 359 367
27. Y. Matsui, M. Inobe, H. Okamoto, S. Chiba, T. Shimizu, and A. Kitabatake Blockade of T cell costimulatory signals using adenovirus vectors prevents both the induction and the progression of experimental autoimmune myocarditis J. Mol. Cell Cardiol. 34 2002 279 295
28. K. Node, M. Fujita, M. Kitakaze, M. Hori, and J.K. Liao Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy Circulation 108 2003 839 843
29. T. Ito, U. Ikeda, M. Shimpo, R. Ohki, M. Takahashi, and K. Yamamoto HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells Cardiovasc. Drugs Ther. 16 2002 121 126
30. I. Inoue, S. Goto, K. Mizotani, T. Awata, T. Mastunaga, and S. Kawai Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells Life Sci. 67 2000 863 876
31. S. Youssef, O. Stuve, J.C. Patarroyo, P.J. Ruiz, J.L. Radosevich, and E.M. Hur The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease Nature 420 2002 78 84
32. O. Aktas, S. Waiczies, A. Smorodchenko, J. Dorr, B. Seeger, and T. Prozorovski Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin J. Exp. Med. 197 2003 725 733
33. A. McKay, B.P. Leung, I.B. McInnes, N.C. Thomson, and F.Y. Liew A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma J. Immunol. 172 2004 2903 2908
34. S.B. Haudek, D.D. Bryant, and B.P. Giroir Differential regulation of myocardial NF kappa B following acute or chronic TNF-alpha exposure J. Mol. Cell Cardiol. 33 2001 1263 1271
35. F.L. Tse, J.M. Jaffe, and A. Troendle Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers J. Clin. Pharmacol. 32 1992 630 638
36. M. Katoh, Y. Kurosawa, K. Tanaka, A. Watanabe, H. Doi, and H. Narita Fluvastatin inhibits O2- and ICAM-1 levels in a rat model with aortic remodeling induced by pressure overload Am. J. Physiol. Heart Circ. Physiol. 281 2001 H655 H660
37. F. Fischetti, R. Carretta, G. Borotto, P. Durigutto, R. Bulla, and P.L. Meroni Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement-mediated acute inflammation Clin. Exp. Immunol. 135 2004 186 193
38. T. Kita, M.S. Brown, and J.L. Goldstein Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase J. Clin. Invest. 66 1980 1094 1100